切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2022, Vol. 12 ›› Issue (05) : 316 -320. doi: 10.3877/cma.j.issn.2095-2007.2022.05.011

综述

硒制剂在甲状腺相关性眼病治疗中的研究进展
张鹏1, 张朝霞2, 闫春芳3, 孙斌3,()   
  1. 1. 030001 太原,山西医科大学第一临床医学院2019级硕士研究生
    2. 030002 太原,山西省眼科医院眼底病科 眼科学山西省重点实验室
    3. 030002 太原,山西省眼科医院眼眶病科
  • 收稿日期:2021-12-27 出版日期:2022-10-28
  • 通信作者: 孙斌
  • 基金资助:
    山西省中医药管理局传承创新项目(2020ZYYC059); 山西省医学重点科研项目(2020XM07); 眼科学山西省重点实验室培育项目(2020SYS12)

Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy

Peng Zhang1, Zhaoxia Zhang2, Chunfang Yan3, Bin Sun3,()   

  1. 1. Master′s degree 2019, First Clinical Colleage of Shanxi Medical University, Taiyuan 030001, China
    2. Department of Fundus, Shanxi Eye Hospital, Shanxi Province Key Laborary of Ophthalmology, Taiyuan 030002, China
    3. Department of Orbital Ophthalmology, Shanxi Eye Hospital, Taiyuan 030002, China
  • Received:2021-12-27 Published:2022-10-28
  • Corresponding author: Bin Sun
引用本文:

张鹏, 张朝霞, 闫春芳, 孙斌. 硒制剂在甲状腺相关性眼病治疗中的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(05): 316-320.

Peng Zhang, Zhaoxia Zhang, Chunfang Yan, Bin Sun. Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(05): 316-320.

甲状腺相关性眼病(TAO)是与自身免疫性甲状腺疾病相关的器官特异性自身免疫性疾病,在成人眼眶病中居首位。硒是人体必不可少的生物微量元素,以硒蛋白质的形式维持机体功能。有研究结果表明,硒对轻度活动性TAO具有疗效;同时,欧洲Graves眼病诊疗指南推荐对早期轻度患者给予硒制剂治疗,改善眼部症状,提高患者的生活质量,防止疾病恶化。但目前其机制尚不明确。因此,本文中笔者就硒制剂在TAO诊疗中作用机制、应用及其前景的研究进展进行综述。

Thyroid associated ophthalmopathy (TAO) is an organ specific autoimmune disease related to autoimmune thyroid disease, which ranks first in adult orbital disease. Selenium is an essential biological trace element in human body, which maintains the body function through the action of selenium protein. It has demonstrated that selenium has a certain effect on mild active TAO. At the same time, the European Graves′ ophthalmopathy collaborative group on Graves orbitopathy clinical practice guidlines recommend that the early mild TAO patients should be treated with selenium, which can improve the eye symptoms, the quality of life and prevent the disease from escalating. However, its mechanism is still unclear. Based on these, the treatment mechanism, application and its prospect of selenium preparation in TAO were reviewed.

图1 眶周组织与甲状腺的共同抗原学说示意图
[1]
邵毅,陈偲翊,廖许琳. 2019甲状腺相关性眼病管理实用指南解读[J]. 国际眼科杂志202121(8):1408-1411.
[2]
Kieliszek M. Selenium fascinating microelement, properties and sources in food[J]. Molecules, 2019, 24(7): 1318-1322.
[3]
Gontarz-Nowak K, Szychlińska M, Matuszewski W, et al. Current knowledge on Graves′ orbitopathy[J]. J Clin Med, 2020, 10(1): 30-32.
[4]
姬璇,张朝霞,闫春芳,等. 甲状腺相关性眼病氧化应激反应的研究进展[J/OL]. 中华眼科医学杂志(电子版)202111(2):124-128.
[5]
Nessel TA, Gupta V. Selenium[M]. Treasure Island (FL) : StatPearls, 2021.
[6]
Lumyongsatien M, Bhaktikamala U, Thongtong P, et al. Relative selenium insufficiency is a risk factor for developing severe Graves′ orbitopathy: a case-control study[J]. BMJ Open Ophthalmol, 2021, 6(1): e000713.
[7]
Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: molecular pathways and physiological roles[J]. Physiol Rev, 2014, 94(3): 739-777.
[8]
Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases[J]. Endocr Rev, 2002, 23(1): 38-89.
[9]
易春峰,李元红. 硒预防心血管病的研究进展[J]. 中国老年学杂志201535(12):3470-3471.
[10]
Wu Q, Rayman MP, Lv H, et al. Low Population Selenium Status Is Associated With Increased Prevalence of Thyroid Disease[J]. J Clin Endocrinol Metab, 2015, 100(11): 4037-4047.
[11]
Bülow PI, Knudsen N, Carlé A, et al. Serum selenium is low in newly diagnosed Graves′ disease: a population-based study[J]. Clin Endocrinol (Oxf), 2013, 79(4): 584-590.
[12]
Wertenbruch T, Willenberg HS, Sagert C, et al. Serum selenium levels in patients with remission and relapse of graves′ disease[J]. J Med Chem, 2007, 3(3): 281-284.
[13]
Arikan TA. Plasma selenium levels in first trimester pregnant women with hyperthyroidism and the relationship with thyroid hormone status[J]. Biol Trace Elem Res, 2015, 167(2): 194-199.
[14]
Wang W, Mao J, Zhao J, et al. Decreased thyroid peroxidase antibody titer in response to selenium supplementation in autoimmune thyroiditis and the influence of a selenoprotein P gene polymorphism: a prospective, multicenter study in China[J]. Thyroid, 2018, 28(12): 1674-1681.
[15]
Qiu Y, Xing Z, Xiang Q, et al. Insufficient evidence to support the clinical efficacy of selenium supplementation for patients with chronic autoimmune thyroiditis[J]. Endocrine, 2021, 73(2): 384-397.
[16]
Winther KH, Rayman MP, Bonnema SJ, et al. Selenium in thyroid disorders——Essential knowledge for clinicians[J]. Nat Rev Endocrinol, 2020, 16(3): 165-176.
[17]
Khong JJ, Goldstein RF, Sanders KM, et al. Serum selenium status in Graves′ disease with and without orbitopathy: a case-control study[J]. Clin Endocrinol, 2014, 80(6): 905-910.
[18]
Duntas LH, Benvenga S. Selenium: an element for life[J]. Endocrine, 2015, 48(3): 756-775.
[19]
Marinò M, Menconi F, Dottore GR, et al. Selenium in Graves hyperthyroidism and orbitopathy[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(4S1): S105-S110.
[20]
Shreenath AP, Ameer MA, Dooley J. Selenium deficiency[M]. Treasure Island (FL) : StatPearls, 2021.
[21]
Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves′ orbitopathy[J]. N Engl J Med, 2011, 364(20): 1920-1931.
[22]
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the Management of Graves′ Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.
[23]
朴司晨. 硒干预轻、中度Graves眼病的安慰剂对照临床研究[D]. 北京:中国医科大学,2017.
[24]
肖新怀,陈澍,苏丽芳. 硒辅助治疗Graves病伴轻度突眼的临床疗效[J]. 中国现代医学杂志201727(11):91-94.
[25]
张祎,张险峰,韩辉,等. 中小剂量甲泼尼龙联合甲氨蝶呤与硒酵母对Graves眼病的疗效观察[J]. 中华内分泌代谢杂志201625(1):24-26.
[26]
柴佩韦. 硒补充疗法对甲状腺相关眼病治疗机制的研究进展[J]. 中华实验眼科杂志201735(9):857-861.
[27]
Marinò M, Dottore GR, Leo M, et al. Mechanistic pathways of selenium in the treatment of Graves′ disease and Graves′ orbitopathy[J]. Horm Metab Res, 2018, 50(12): 887-893.
[28]
Lanzolla G, Marcocci C, Marinò M. Antioxidant therapy in Graves′ orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11: 608733.
[29]
Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves′ hyperthyroidism and eye disease[J]. Front Endocrinol (Lausanne), 2020, 11: 608428.
[30]
Kieliszek M, Baejak S. Current knowledge on the importance of selenium in food for living organisms: a review[J]. Molecules (Basel, Switzerland), 2016, 21(5): 451-456.
[31]
ZarkoviĉM. The role of oxidative stress on the pathogenesis of graves′ disease[J]. J Thyroid Res, 2012: 302537.
[32]
Hasani M, Djalalinia S, Khazdooz M, et al. Effect of selenium supplementation on antioxidant markers: a systematic review and meta-analysis of randomized controlled trials[J]. Hormones (Athens), 2019, 18(4): 451-462.
[33]
Fernández-Lázaro D, Fernandez-Lazaro CI, Mielgo-Ayuso J, et al. The role of selenium mineral trace element in exercise: antioxidant defense system, muscle performance, hormone response, and athletic performance: a systematic review[J]. Nutrients, 2020, 12(6): 1790.
[34]
Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities[J]. Antioxid Redox Signal, 2012, 16(7): 705-743.
[35]
Rotondo DG, Leo M, Casini G, et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves′ orbitopathy[J]. Thyroid, 2017, 27(2): 271-278.
[36]
张方华,阎胜利,余霄龙,等. 亚硒酸钠对体外培养人甲状腺细胞氧化损伤的影响[J]. 免疫学杂志200824(2):139-141.
[37]
Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity[J]. Proc Natl Acad Sci U S A, 1996, 93(3): 1006-1011.
[38]
张辉,刘明法,李少臣,等. 硒和蛋白质对大鼠心肌形态结构及谷胱甘肽过氧化物酶和线粒体型硫氧还蛋白还原酶表达的影响[J]. 中国地方病学杂志201231(1):40-45.
[39]
何志伟,胡欣,陈国芳,等. 甲状腺相关性眼病病因、发病机制及免疫靶向治疗的研究进展[J]. 山东医药202060(28):90-93.
[40]
Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J]. Invest Ophth Vis Sci, 2014, 55(3): 1735-1748.
[41]
Bahn RS. Current insights into the pathogenesis of Graves′ ophthalmopathy[J]. Horm Metab Res, 2015, 47(10): 773-778.
[42]
Lantz M, Planck T, Asman P, et al. Increased TRAb and/or low anti-TPO titers at diagnosis of graves′ disease are associated with an increased risk of developing ophthalmopathy after onset[J]. Exp Clin Endocrinol Diabetes, 2014, 122(2): 113-117.
[43]
Xu B, Wu D, Ying H, et al. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves′ disease[J]. Turk J Med Sci, 2019, 49(3): 715-722.
[44]
Wichman J, Winther KH, Bonnema SJ, et al. Selenium Supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis[J]. Thyroid, 2016, 26(12): 1681-1692.
[45]
Hai YP, Lee ACH, Frommer L, et al. Immunohistochemical analysis of human orbital tissue in Graves′ orbitopathy[J]. J Endocrinol Invest, 2020, 43(2): 123-137.
[46]
Balázs C, Kaczur V. Effect of selenium on HLA-DR EXPRESSION OF Thyrocytes[J]. Autoimmune Dis, 2012: 374635.
[47]
Shrimali RK, Irons RD, Carlson BA, et al. Selenoproteins mediate T cell immunity through an antioxidant mechanism[J]. J Biol Chem, 2008, 283(29): 20181-20185.
[48]
Tinkov AA, Ajsuvakova OP, Filippini T, et al. Selenium and selenoproteins in adipose tissue physiology and obesity[J]. Biomolecules, 2020, 10(4): 658.
[49]
Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves′ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves′ orbitopathy[J]. Eur J Endocrinol, 2021, 185(4): G43-G67.
[50]
中国营养学会. 最新中国居民膳食营养素参考摄入量要点精编[J]. 健康指南:中老年201628(11):32-33.
[51]
Rayman MP. Selenium and human health[J]. Lancet, 2012, 379(9822): 1256-1268.
[52]
乔晶. Graves眼病患者血清外泌体miRNA表达谱的差异性分析及硒干预对其远期预后影响的前瞻队列研究[D]. 北京:中国医科大学,2021.
[53]
王英爽,王雅文,张新玮. 眼眶减压术联合硒酵母片治疗对Graves伴突眼症患者疗效及对TSH、HA水平的影响[J]. 湖南师范大学学报(医学版)20207(1):158-161.
[54]
李丹丹,刘扬,元荣荣,等. 硒酵母联合甲巯咪唑治疗Graves病伴轻度突眼的临床效果[J]. 河南医学研究202029(2):217-220.
[55]
Almanza-Monterrubio M, Garnica-Hayashi L, Dávila-Camargo A, et al. Oral selenium improved the disease activity in patients with mild Graves′ orbitopathy[J]. J Fr Ophtalmol, 2021, 44(5): 643-651.
[1] 尹娟, 杨兴, 李平, 徐旻馨, 鲍玉, 张志鹏, 薛慧. 低强度脉冲式超声波在脂多糖诱导的RAW264.7巨噬细胞分化中的抗炎和抗氧化作用[J]. 中华口腔医学研究杂志(电子版), 2023, 17(01): 26-36.
[2] 钟轼, 李斌飞, 温君琳, 古晨, 廖小卒. 右美托咪定缓解神经病理性疼痛作用机制的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(03): 237-240.
[3] 刘骏, 朱霁, 殷骏. 右美托咪定对腹股沟疝手术麻醉效果及安全性的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 570-573.
[4] 杨斌, 胡光太, 周纲. 完整剥离和横断疝囊在单侧腹股沟斜疝经腹腹膜前修补术中的疗效比较[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(01): 42-46.
[5] 张瑞琪, 张丽娟, 孙斌. 甲状腺相关性眼病表观遗传学的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 226-230.
[6] 尚慧娟, 袁晓冬. 机械取栓术后应用依达拉奉右崁醇对急性缺血性脑卒中预后的改善[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 295-301.
[7] 阿迪莱·阿卜杜热西提, 费奥, 邢晓雯, 谢胜强, 张睿, 兰晓娟, 程岗. 三种模拟创伤性脑损伤体外细胞模型的损伤特征比较[J]. 中华神经创伤外科电子杂志, 2023, 09(02): 69-75.
[8] 邹勇, 顾应江, 丁昊, 杨呈浩, 陈岷辉, 蔡昱. 基于Nrf2/HO-1及NF-κB信号通路探讨葛根素对大鼠脑出血后早期炎症反应及氧化应激反应的影响[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 271-277.
[9] 张敏洁, 张小杉, 段莎莎, 施依璐, 赵捷, 白天昊, 王雅晳. 氢气治疗心肌缺血再灌注损伤的作用机制及展望[J]. 中华临床医师杂志(电子版), 2023, 17(06): 744-748.
[10] 孙凤兰, 周萍, 程兴璞, 张倩倩. 腹腔镜全子宫切除术对子宫肌瘤患者机体氧化应激损伤及术后并发症的影响[J]. 中华临床医师杂志(电子版), 2023, 17(02): 149-153.
[11] 岑妍慧, 高月, 林江, 刘鹏, 贾微, 杨瑞, 黄威, 刘鑫, 黄泽萍, 宁志莹. 水解南珠液通过Wnt/β-catenin通路调节细胞自噬对人微血管内皮细胞氧化应激损伤的影响[J]. 中华临床医师杂志(电子版), 2023, 17(01): 72-79.
[12] 靳潇潇, 郑聪, 何文强. 肾结石与高血压关系的研究进展[J]. 中华临床医师杂志(电子版), 2022, 16(12): 1284-1288.
[13] 郑家阳, 林锦钰, 王张民, 罗琴, 张琳, 秦立强, 陈婧司, 尹雪斌. 中老年硒及硒蛋白水平与血脂的关联性研究[J]. 中华临床医师杂志(电子版), 2022, 16(12): 1175-1179.
[14] 王正宇, 孙琳. 硒联合不同药物治疗桥本甲状腺炎的研究进展[J]. 中华诊断学电子杂志, 2023, 11(02): 125-127.
[15] 买买提·依斯热依力, 依力汗·依明, 王永康, 阿巴伯克力·乌斯曼, 艾克拜尔·艾力, 李义亮, 克力木·阿不都热依木. 氧化应激对3T3-L1前脂肪细胞中GLP-1/DPP-4信号通路以及炎症因子表达的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 186-191.
阅读次数
全文


摘要